Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) CFO William J. Peters sold 2,407 shares of the firm’s stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $17.59, for a total transaction of $42,339.13. Following the completion of the sale, the chief financial officer now owns 86,836 shares in the company, valued at approximately $1,527,445.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

William J. Peters also recently made the following trade(s):

  • On Monday, July 9th, William J. Peters sold 3,250 shares of Amphastar Pharmaceuticals stock. The stock was sold at an average price of $16.46, for a total transaction of $53,495.00.

AMPH traded down $0.22 during trading on Friday, reaching $17.82. 116,001 shares of the company’s stock were exchanged, compared to its average volume of 200,452. Amphastar Pharmaceuticals Inc has a fifty-two week low of $14.40 and a fifty-two week high of $20.45. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.94 and a quick ratio of 1.24. The company has a market capitalization of $801.16 million, a P/E ratio of 46.89, a P/E/G ratio of 3.24 and a beta of 1.40.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, August 8th. The company reported $0.03 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.08 by ($0.05). Amphastar Pharmaceuticals had a positive return on equity of 2.15% and a negative net margin of 3.39%. The business had revenue of $71.00 million for the quarter, compared to analyst estimates of $64.22 million. During the same quarter in the prior year, the firm earned $0.11 EPS. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. equities research analysts expect that Amphastar Pharmaceuticals Inc will post 0.24 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of AMPH. BlackRock Inc. boosted its stake in Amphastar Pharmaceuticals by 5.9% during the second quarter. BlackRock Inc. now owns 5,720,183 shares of the company’s stock worth $87,291,000 after buying an additional 318,360 shares in the last quarter. Cortina Asset Management LLC acquired a new stake in Amphastar Pharmaceuticals during the first quarter worth $4,907,000. Mackay Shields LLC acquired a new stake in Amphastar Pharmaceuticals during the first quarter worth $4,294,000. Federated Investors Inc. PA boosted its stake in Amphastar Pharmaceuticals by 21.6% during the second quarter. Federated Investors Inc. PA now owns 1,276,552 shares of the company’s stock worth $19,480,000 after buying an additional 227,142 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Amphastar Pharmaceuticals by 5.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,769,533 shares of the company’s stock worth $27,004,000 after buying an additional 84,085 shares in the last quarter. Hedge funds and other institutional investors own 43.66% of the company’s stock.

AMPH has been the topic of several research analyst reports. ValuEngine upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 15th. Finally, BidaskClub upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 19th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $21.00.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Recommended Story: Dividend

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.